Immunity to Hepatitis B Vaccine in Thalassaemic Patients based on the Time Passed from Vaccination

Authors

  • A Hoseininasab Assistant Professor of Pediatrics, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran Assistant Professor of Pediatrics, Tropical and Infectious Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran
  • A.A Vahidi Associate Professor of Pediatrics, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
  • M.H Daei-parizi Professor of Pediatrics, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
  • M.H Torabinejhad Assistant Professor of Pediatrics, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
  • R Bahrami Pediatrics Specialist
Abstract:

Background & Aims: Hepatitis B virus is one of the causes of acute and chronic hepatitis. Due to multiple hospitalization and blood transfusion, thalassaemic patients are at higher risk of this infection. Duration of the immunity after vaccination in this high-risk group and the need for booster vaccination is uncertain. The aim of this study was to find antibody titration and immunity to Hepatitis B vaccine in thalassaemic patients at different time intervals after vaccination. Methods: A total of 454 thalassaemic patients in Kerman were evaluated in this study. All patients had been vaccinated with recombinant hepatitis B vaccine according to the national vaccination program. On the base of the time interval after vaccination, patients were divided into the 6 groups of 1 year, 1-2, 2-3, 3-4, 4-5 and 5 years. According to their anti-HBs antibody titer, patients were classified as non-immune (<10 IU/L), semi-immune (10-100 IU/L) and complete-immune (>100 IU/L). Results: The rates of non-immune cases in the 6 considered groups were respectively 3.28%, 3.3%, 5.7%, 19%, 33.3% and 58.2%. Conclusion: Three years after Hepatitis B vaccination in thalassaemic patients anti-HBs antibody levels decreases significantly. Therefore, evaluation of hepatitis B immunity level and performing booster vaccination after this period should be considered.

Download for Free

Sign up for free to access the full text

Already have an account?login

similar resources

can Isolated hepatitis B core antibody in HIV-infected patients response to hepatitis B vaccine help to elucidate the cause?

full text

Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier

Background: In Iran scince 1992, hepatitis B vaccination was a part of the national vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis B. The aim ofthis study was to evaluate the long &ndash; term persistence of immunity. Methods: This cross-sectional analytical study was conducted on children and adolescents aged between 6-18 years in Birjand, who recei...

full text

The Study of Cerumen Hepatitis B Infection in Chronic Hepatitis B Patients by Real-Time PCR

Introduction: The hepatitis B is a viral infection that causes a big problem globally. About 2 billion people worldwide are infected and there are now about 400 million HBV-DNA carriers around the world. HBV infection is the ninth cause of death worldwide and infects about 350 million new cases each year in the world. HBV-DNA can be spotted in different body secretions and fluids, including se...

full text

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy

Objective (s):The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients. Materials and Methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples...

full text

Immune Response to Standard Hepatitis B Vaccination in HIV-Infected Patients

Background: Due to their similar routes of transmission, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection occurs considerably. HBV infection progresses more rapidly in HIV-infected patients. Therefore, HBV vaccination of all non-immune HIV infected patients is recommended. On the other hand, HIV-infected subjects have suboptimal responses to HBV vaccine. In this study...

full text

An Investigation of the Immune Response to Hepatitis B Vaccination in Hemodialysis Patients at Dialysis Centers of Tehran (2016)

Background: Hemodialysis (HD) patients are at an increased risk of acquiring the hepatitis B (HB) virus and having lower protective antibody levels as well as shorter durations of seroprotection. This study aims to determine the immune response of HB vaccination in HD patients referring to dialysis centers of the Tehran North Health Network. Materials and Methods: This descriptive study was co...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 19  issue 5

pages  433- 439

publication date 2012-09-01

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023